UMIN-CTR History
Name： UMIN ID：
| Unique ID issued by UMIN | UMIN000009602 |
|---|---|
| Receipt number | R000011260 |
| Scientific Title | A randomized Phase II Study of Bevacizumab in Combination with Docetaxel or S-1 as second line therapy in wild-type EGFR Patients with Non-Squamous Non-Small-Cell Lung Cancer. After failure to first line therapy, platinum doublet plus bevacizumab. |
| Date of disclosure of the study information | 2012/12/21 |
| Last modified on | 2021/07/06 14:00:15 |
| No. | Disposal | Last modified on | Item of update | |
|---|---|---|---|---|
| 1 | Insert | 2012/12/21 11:14:54 | ||
| 2 | Update | 2021/07/06 14:00:15 | Recruitment status Date of IRB |
